drugset / Trial / NCT04587622
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with varying degrees of hepatic impairment.
Timeline
- Start
- 2020-10-30
- Primary completion
- 2022-09-15
- Completion
- 2022-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icenticaftor | Small molecule | 300 mg | Oral |